LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, will host a conference call and slide presentation to discuss preliminary results of its Phase II study looking at the incidence and severity of diarrhea in patients with early-stage HER2-positive breast cancer treated with extended adjuvant neratinib monotherapy and prophylactic loperamide. The call will be held at 4:15 p.m. EST (1:15 p.m. PST) on December 21, 2015.
